The StrataNGS test has received coverage under Medicare by Palmetto GBA, a Medicare Administrative Contractor, for patients with advanced stages (III or IV), recurrent, relapsed, refractory, and/or metastatic solid tumors.
As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing.
